Clinical Development of Gene Therapy Products for Rare Diseases
The FDA’s Center for Biologics Evaluation and Research (CBER) Office of Tissues and Advanced Therapies (OTAT) is hosting a virtual town hall to answer stakeholder questions related to the clinical […]